ALK and neoplasm: It is worth mentioning that subset analyses did not show clear benefits for atezolizumab in patients who were never-smokers, those with epidermal growth factor (EGFR)- or anaplastic lymphoma kinase (ALK)-mutated tumors, and in those with tumor expression of PD-L1 in less than 50% of neoplastic cells, although these were not powered analyses.